CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing its novel Probody® platform to enable drugging previously considered undruggable targets. Our pipeline includes potential first-in-class therapeutic candidates CX-2009, a wholly owned CD166-targeting Probody drug conjugate, and CX-2029, a CD71-targeting Probody drug conjugate partnered with AbbVie, both of which are in Phase 2. Our clinical-stage portfolio includes potential best-in-class immunotherapeutic candidates against clinically validated targets. Our strategic collaborations include AbbVie, Amgen, Astellas and Bristol Myers Squibb.